Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
Scientific Reports|April 12, 2020
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity MeasurementsKristian C Becker, Lydia Coulter Kwee, Megan L Neely, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Cardiology|August 14, 2023
Can a best practice advisory improve anticoagulation prescribing to reduce stroke risk in patients with atrial fibrillation?Mark H Eckman, Ruth Wise, Carol Knochelmann, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
Nature Reviews. Cardiology|January 14, 2022
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers ColloquiumDiana A Gorog, Robert F Storey, Paul A Gurbel, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
Journal of the American Heart Association|August 19, 2020
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) TrialIda Gregersen, Annika E Michelsen, Ngoc Nguyen Lunde, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
Scientific Reports|April 12, 2020
Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity MeasurementsKristian C Becker, Lydia Coulter Kwee, Megan L Neely, et al.
Circulation. Cardiovascular Quality and Outcomes|June 14, 2013
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experienceKenneth W Mahaffey, Anne S Hellkamp, Manesh R Patel, et al.
Journal of Cardiology|August 14, 2023
Can a best practice advisory improve anticoagulation prescribing to reduce stroke risk in patients with atrial fibrillation?Mark H Eckman, Ruth Wise, Carol Knochelmann, et al.
European Heart Journal|September 12, 2014
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF TrialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
Nature Reviews. Cardiology|January 14, 2022
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers ColloquiumDiana A Gorog, Robert F Storey, Paul A Gurbel, et al.
International Journal of Cardiology|March 7, 2018
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFAdam S Barnett, Derek D Cyr, Shaun G Goodman, et al.
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
Journal of the American Heart Association|August 19, 2020
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) TrialIda Gregersen, Annika E Michelsen, Ngoc Nguyen Lunde, et al.
Heart Rhythm|May 17, 2014
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trialBenjamin A Steinberg, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 44